Kyoung Soo Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kyoung Soo Lim has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Joo-Youn Cho
Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea
10 shared publications - Kyung-Sang Yu
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Republic of Korea
8 shared publications - In-Jin Jang
Department of Pharmacology, Seoul National University College of Medicine, Clinical Pharmacology Unit, Korea
5 shared publications Sang-Goo Shin
5 shared publicationsSeo Hyun Yoon
5 shared publicationsKyung-Sang Yu
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital
4 shared publications
Latest Publications
- 1 January 2017
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 32 (1) , 20-26
Pharmacokinetics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly compared with younger adults
Escitalopram is the (S)-enantiomer of citalopram that has a potential QT prolonging effect. In this study, 12 healthy elderly individuals received a single oral dose of escitalopram (20 mg), and their pharmacokinetics and QT effect data were compared with data from 33 younger adults obtained in a previous study. Serial blood samples for pharmacokinetic analysis were collected and ECG was performed up to 48 h postdose. The elderly and younger adults showed similar pharmacokinetic profiles. The geometric mean ratios (90% confidence interval) of the elderly compared with the younger adults were 1.02 (0.89-1.17) and 1.01 (0.86-1.17) for the maximum plasma concentration and area under the concentration-time curve, respectively. The mean baseline-adjusted QT (dQT) time profiles were similar and the mean values of maximum dQT were not significantly different between the elderly and the younger adults. The linear mixed-effect model indicated a weak but positive relationship between the escitalopram concentration and dQT, with an estimated coefficient of concentration of 0.43-0.54. In conclusion, the pharmacokinetics and QT effect of a single dose of escitalopram observed in the elderly without comorbidities and younger adults were generally similar.
- 1 January 2017
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 32 (1) , 20-26
Pharmacokinetics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly compared with younger adults
Escitalopram is the (S)-enantiomer of citalopram that has a potential QT prolonging effect. In this study, 12 healthy elderly individuals received a single oral dose of escitalopram (20 mg), and their pharmacokinetics and QT effect data were compared with data from 33 younger adults obtained in a previous study. Serial blood samples for pharmacokinetic analysis were collected and ECG was performed up to 48 h postdose. The elderly and younger adults showed similar pharmacokinetic profiles. The geometric mean ratios (90% confidence interval) of the elderly compared with the younger adults were 1.02 (0.89-1.17) and 1.01 (0.86-1.17) for the maximum plasma concentration and area under the concentration-time curve, respectively. The mean baseline-adjusted QT (dQT) time profiles were similar and the mean values of maximum dQT were not significantly different between the elderly and the younger adults. The linear mixed-effect model indicated a weak but positive relationship between the escitalopram concentration and dQT, with an estimated coefficient of concentration of 0.43-0.54. In conclusion, the pharmacokinetics and QT effect of a single dose of escitalopram observed in the elderly without comorbidities and younger adults were generally similar.
- 1 October 2014
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 36 (5) , 606-611
Trough Concentration Over 12.1 mg/L is a Major Risk Factor of Vancomycin-Related Nephrotoxicity in Patients With Therapeutic Drug Monitoring
Background: High doses of vancomycin increase the risk of nephrotoxicity, but the quantitative relationship between vancomycin exposure and nephrotoxicity is still controversial. This study evaluated the relationship between vancomycin trough concentration and nephrotoxicity, and risk factors for nephrotoxicity in patients undergoing therapeutic drug monitoring. Methods: A total of 1269 cases from patients who underwent therapeutic drug monitoring were collected from 2006 to 2010. Receiver operating characteristic curve analysis was used to evaluate the relationship between trough concentration and the incidence of nephrotoxicity. Logistic regression using the generalized Least Absolute Shrinkage and Selection Operator (lasso) method was used to evaluate possible risk factors for nephrotoxicity. The data were divided into high/low-concentration groups by the cutoff value obtained from the receiver operating characteristic curve, and additional logistic regression using the generalized lasso method was performed for each group. Results: The cutoff value of the vancomycin trough concentration was 12.1 mg/L. Patients with high concentrations (>12.1 mg/L) were more likely to develop nephrotoxicity (odds ratio = 16.0, 95% confidence interval, 8.2–31.1). The vancomycin trough concentration was the only significant risk factor for nephrotoxicity identified using the generalized lasso (P < 0.001). In contrast, no factor was associated with nephrotoxicity in the low-concentration group. Conclusions: Vancomycin trough concentrations over 12.1 mg/L were associated with an increased risk of nephrotoxicity. This is lower than the known threshold. Trough vancomycin concentration over the threshold was the only risk factor of nephrotoxicity among demographic factors, dosing regimen, and other clinical conditions in this study. It is suggested that vancomycin trough concentrations greater than 12.1 mg/L require close monitoring for nephrotoxicity.
- 1 October 2014
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 36 (5) , 606-611
Trough Concentration Over 12.1 mg/L is a Major Risk Factor of Vancomycin-Related Nephrotoxicity in Patients With Therapeutic Drug Monitoring
Background: High doses of vancomycin increase the risk of nephrotoxicity, but the quantitative relationship between vancomycin exposure and nephrotoxicity is still controversial. This study evaluated the relationship between vancomycin trough concentration and nephrotoxicity, and risk factors for nephrotoxicity in patients undergoing therapeutic drug monitoring. Methods: A total of 1269 cases from patients who underwent therapeutic drug monitoring were collected from 2006 to 2010. Receiver operating characteristic curve analysis was used to evaluate the relationship between trough concentration and the incidence of nephrotoxicity. Logistic regression using the generalized Least Absolute Shrinkage and Selection Operator (lasso) method was used to evaluate possible risk factors for nephrotoxicity. The data were divided into high/low-concentration groups by the cutoff value obtained from the receiver operating characteristic curve, and additional logistic regression using the generalized lasso method was performed for each group. Results: The cutoff value of the vancomycin trough concentration was 12.1 mg/L. Patients with high concentrations (>12.1 mg/L) were more likely to develop nephrotoxicity (odds ratio = 16.0, 95% confidence interval, 8.2–31.1). The vancomycin trough concentration was the only significant risk factor for nephrotoxicity identified using the generalized lasso (P < 0.001). In contrast, no factor was associated with nephrotoxicity in the low-concentration group. Conclusions: Vancomycin trough concentrations over 12.1 mg/L were associated with an increased risk of nephrotoxicity. This is lower than the known threshold. Trough vancomycin concentration over the threshold was the only risk factor of nephrotoxicity among demographic factors, dosing regimen, and other clinical conditions in this study. It is suggested that vancomycin trough concentrations greater than 12.1 mg/L require close monitoring for nephrotoxicity.
- Open Access
- 2 April 2014
- Published by Springer Nature in Drugs in R&D
- Vol. 14 (2) , 63-71
The Effects of Moxifloxacin on QTc Interval in Healthy Korean Male Subjects
Moxifloxacin 400 mg is a widely used positive control in thorough QT (TQT) studies, but its QT-prolonging effects in Korean subjects have not been studied. The present study was conducted to collect pilot data in Korean subjects after moxifloxacin administration to evaluate the adequacy of moxifloxacin as a positive control.
- 2 April 2014
- Published by Springer Nature in Drugs in R&D
- Vol. 14 (2) , 63-71
Open AccessThe Effects of Moxifloxacin on QTc Interval in Healthy Korean Male Subjects
Moxifloxacin 400 mg is a widely used positive control in thorough QT (TQT) studies, but its QT-prolonging effects in Korean subjects have not been studied. The present study was conducted to collect pilot data in Korean subjects after moxifloxacin administration to evaluate the adequacy of moxifloxacin as a positive control.
- 1 June 2013
- Published by Elsevier in Contraception
- Vol. 87 (6) , 750-755
Pharmacokinetic study of single and multiple oral administrations of 2 mg dienogest in healthy Korean women
- 1 June 2013
- Published by Elsevier in Contraception
- Vol. 87 (6) , 750-755
Pharmacokinetic study of single and multiple oral administrations of 2 mg dienogest in healthy Korean women
- Open Access
- 19 March 2013
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 113 (2) , 113-125
Pharmacokinetic-Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers
- 19 March 2013
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 113 (2) , 113-125
Open AccessPharmacokinetic-Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers
- 1 January 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (1) , 75-81
Increased Systemic Exposure of Fimasartan, an Angiotensin II Receptor Antagonist, by Ketoconazole and Rifampicin
The authors studied the effects of ketoconazole and rifampicin on the pharmacokinetics of a single dose of fimasartan (BR‐A‐657), a newly developed angiotensin II receptor antagonist for the treatment of hypertension, in 22 healthy participants. Ketoconazole increased the maximumplasma concentration (Cmax) and area under the plasma concentration vs time curve to infinity (AUC⧝ of fimasartan by 2.47‐fold (90% confidence interval [CI], 1.61‐3.79) and 2.03‐fold (1.56‐2.64), respectively. Concomitant administration of rifampicin increased the Cmax and AUC∞ of fimasartan by 10.33‐fold (90% CI, 6.74‐15.81) and 4.60‐fold (3.54‐5.97). In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a Ki of 107.7 µM, and rifampicin inhibited OAT1‐ and OATP1B1‐mediated fimasartan transport with a Ki of 212 µM and 12.2 µM, respectively. The systemic exposure of fimasartan was significantly increased by coadministration of ketoconazole or rifampicin in healthy volunteers. This is consistent with the in vitro results, in which fimasartan is a substrate of CYP3A and OATP1B1.
- 1 January 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (1) , 75-81
Increased Systemic Exposure of Fimasartan, an Angiotensin II Receptor Antagonist, by Ketoconazole and Rifampicin
The authors studied the effects of ketoconazole and rifampicin on the pharmacokinetics of a single dose of fimasartan (BR‐A‐657), a newly developed angiotensin II receptor antagonist for the treatment of hypertension, in 22 healthy participants. Ketoconazole increased the maximumplasma concentration (Cmax) and area under the plasma concentration vs time curve to infinity (AUC⧝ of fimasartan by 2.47‐fold (90% confidence interval [CI], 1.61‐3.79) and 2.03‐fold (1.56‐2.64), respectively. Concomitant administration of rifampicin increased the Cmax and AUC∞ of fimasartan by 10.33‐fold (90% CI, 6.74‐15.81) and 4.60‐fold (3.54‐5.97). In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a Ki of 107.7 µM, and rifampicin inhibited OAT1‐ and OATP1B1‐mediated fimasartan transport with a Ki of 212 µM and 12.2 µM, respectively. The systemic exposure of fimasartan was significantly increased by coadministration of ketoconazole or rifampicin in healthy volunteers. This is consistent with the in vitro results, in which fimasartan is a substrate of CYP3A and OATP1B1.
- Open Access
- 1 January 2013
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Journal of Korean Society for Clinical Pharmacology and Therapeutics
- Vol. 21 (2) , 104-112
Pharmacokinetic Characteristics of Cefcapene Pivoxil Hydrochloride after Single Oral Administration in Healthy Korean Subjects
Rhee SJ, et al. J Korean Soc Clin Pharmacol Ther. 2013 Dec;21(2):104-112. http://dx.doi.org/10.12793/jkscpt.2013.21.2.104
- 1 January 2013
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Journal of Korean Society for Clinical Pharmacology and Therapeutics
- Vol. 21 (2) , 104-112
Open AccessPharmacokinetic Characteristics of Cefcapene Pivoxil Hydrochloride after Single Oral Administration in Healthy Korean Subjects
Rhee SJ, et al. J Korean Soc Clin Pharmacol Ther. 2013 Dec;21(2):104-112. http://dx.doi.org/10.12793/jkscpt.2013.21.2.104
- Open Access
- 1 January 2013
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Journal of Korean Society for Clinical Pharmacology and Therapeutics
- Vol. 21 (1) , 41-51
A Randomized, Open Label, 2-Way Crossover Study to Assess the Pharmacokinetic Characteristics and Skin Irritation of Murupe® Patch Compared with Trast® Patch in Healthy Volunteers
Choi YJ, et al. J Korean Soc Clin Pharmacol Ther. 2013 Jun;21(1):41-51. https://doi.org/10.12793/jkscpt.2013.21.1.41
- 1 January 2013
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Journal of Korean Society for Clinical Pharmacology and Therapeutics
- Vol. 21 (1) , 41-51
Open AccessA Randomized, Open Label, 2-Way Crossover Study to Assess the Pharmacokinetic Characteristics and Skin Irritation of Murupe® Patch Compared with Trast® Patch in Healthy Volunteers
Choi YJ, et al. J Korean Soc Clin Pharmacol Ther. 2013 Jun;21(1):41-51. https://doi.org/10.12793/jkscpt.2013.21.1.41
- 1 October 2012
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 50 (10) , 722-728
Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers
Fesoterodine is a pro-drug of the active metabolite 5-hydroxymethyl tolterodine (5-HMT), a muscarinic receptor antagonist. This study aimed to evaluate the safety profile and pharmacokinetic characteristics of multiple oral doses of sustained-release fesoterodine (fesoterodine SR) in healthy Korean males. A randomized, double-blind, placebo-controlled, multiple-dose study with two oral doses (4 mg and 8 mg) was conducted in healthy Korean male participants. The study drug was administered once daily for 5 days. The plasma concentration of 5-HMT was measured up to 72 hours after the last drug administration. The CYP2D6 genotype was analyzed using polymerase chain reaction (PCR) methods to assess the effect of genetic polymorphisms on the pharmacokinetic parameters. 20 participants completed the study. The mean (SD) areas under the plasma concentration-time curves during the dosing interval (AUCτ) of the 4 mg and 8 mg dose groups were 26.1 (8.0) and 64.2 (30.5) μg·h/ml and the mean peak concentrations (Cmax) were 2.6 (0.7) and 6.0 (2.0) μg/ml, respectively, at steady-state. The mean AUCτ and Cmax of 5-HMT increased in approximately the same proportion as the dose increased. Fesoterodine SR was well tolerated without any serious adverse events or abnormal clinical laboratory findings. Systemic 5-HMT exposure showed dose-proportional characteristics in the 4 mg to 8 mg dose range in healthy Korean males. Thus, 4 mg or 8 mg doses of fesoterodine SR taken once-daily were tolerable in healthy Korean males.
- 1 October 2012
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 50 (10) , 722-728
Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers
Fesoterodine is a pro-drug of the active metabolite 5-hydroxymethyl tolterodine (5-HMT), a muscarinic receptor antagonist. This study aimed to evaluate the safety profile and pharmacokinetic characteristics of multiple oral doses of sustained-release fesoterodine (fesoterodine SR) in healthy Korean males. A randomized, double-blind, placebo-controlled, multiple-dose study with two oral doses (4 mg and 8 mg) was conducted in healthy Korean male participants. The study drug was administered once daily for 5 days. The plasma concentration of 5-HMT was measured up to 72 hours after the last drug administration. The CYP2D6 genotype was analyzed using polymerase chain reaction (PCR) methods to assess the effect of genetic polymorphisms on the pharmacokinetic parameters. 20 participants completed the study. The mean (SD) areas under the plasma concentration-time curves during the dosing interval (AUCτ) of the 4 mg and 8 mg dose groups were 26.1 (8.0) and 64.2 (30.5) μg·h/ml and the mean peak concentrations (Cmax) were 2.6 (0.7) and 6.0 (2.0) μg/ml, respectively, at steady-state. The mean AUCτ and Cmax of 5-HMT increased in approximately the same proportion as the dose increased. Fesoterodine SR was well tolerated without any serious adverse events or abnormal clinical laboratory findings. Systemic 5-HMT exposure showed dose-proportional characteristics in the 4 mg to 8 mg dose range in healthy Korean males. Thus, 4 mg or 8 mg doses of fesoterodine SR taken once-daily were tolerable in healthy Korean males.
- 1 June 2012
- Published by Springer Nature in BioDrugs
- Vol. 26 (3) , 177-184
Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®)
Objective: HD203 is a biosimilar of etanercept, a fusion protein of the ligand-binding portion of the human tumor necrosis factor receptor II linked to the Fc portion of human immunoglobulin G1. Since HD203 is under clinical development, this study was conducted to compare the pharmacokinetics of HD203 with Enbrel ®, the first marketed etanercept. Methods: A double-blind, randomized, single-dose, two-period, two-sequence, crossover study was conducted in 37 healthy volunteers. In each period, 25mg/mL of reconstituted lyophilized reference (Enbrel®) or test product (HD203) was administered subcutaneously, either the reference product followed by the test product, or vice versa. Serial blood samples for pharmacokinetic analysis were taken for 480 hours after dosing, and serum concentrations of the products were determined using a commercial enzyme-linked immunosorbent assay. The geometric mean ratios with 90% confidence intervals for the maximum concentration (Cmax) and the area under the concentration-time curve from time 0 to the last measurable time point (AUC0-t) were estimated. Results: A total of 35 subjects completed the study; serious adverse events were not observed. The mean serum concentration-time profiles of the two products were similar. The Cmax and AUC0-t values of the reference product (mean±standard deviation) were 1.25±0.45mg/L and 283.15 ± 98.57mg*h/L, respectively, while those of the test drug were 1.35 ± 0.47 mg/L and 315.78±99.38 mg*h/L, respectively. The geometric mean ratios (90% confidence intervals) of the test to the reference for Cmax and AUC0-t were 1.08 (1.00, 1.16) and 1.13 (1.05, 1.21), respectively. Conclusions: A single subcutaneous injection of HD203 or Enbrel ® into healthy volunteers appeared to be safe and well tolerated. Comparative pharmacokinetics demonstrated that reconstituted lyophilized HD203 has bioavailability similar to that of Enbrel®.
- 1 June 2012
- Published by Springer Nature in BioDrugs
- Vol. 26 (3) , 177-184
Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®)
Objective: HD203 is a biosimilar of etanercept, a fusion protein of the ligand-binding portion of the human tumor necrosis factor receptor II linked to the Fc portion of human immunoglobulin G1. Since HD203 is under clinical development, this study was conducted to compare the pharmacokinetics of HD203 with Enbrel ®, the first marketed etanercept. Methods: A double-blind, randomized, single-dose, two-period, two-sequence, crossover study was conducted in 37 healthy volunteers. In each period, 25mg/mL of reconstituted lyophilized reference (Enbrel®) or test product (HD203) was administered subcutaneously, either the reference product followed by the test product, or vice versa. Serial blood samples for pharmacokinetic analysis were taken for 480 hours after dosing, and serum concentrations of the products were determined using a commercial enzyme-linked immunosorbent assay. The geometric mean ratios with 90% confidence intervals for the maximum concentration (Cmax) and the area under the concentration-time curve from time 0 to the last measurable time point (AUC0-t) were estimated. Results: A total of 35 subjects completed the study; serious adverse events were not observed. The mean serum concentration-time profiles of the two products were similar. The Cmax and AUC0-t values of the reference product (mean±standard deviation) were 1.25±0.45mg/L and 283.15 ± 98.57mg*h/L, respectively, while those of the test drug were 1.35 ± 0.47 mg/L and 315.78±99.38 mg*h/L, respectively. The geometric mean ratios (90% confidence intervals) of the test to the reference for Cmax and AUC0-t were 1.08 (1.00, 1.16) and 1.13 (1.05, 1.21), respectively. Conclusions: A single subcutaneous injection of HD203 or Enbrel ® into healthy volunteers appeared to be safe and well tolerated. Comparative pharmacokinetics demonstrated that reconstituted lyophilized HD203 has bioavailability similar to that of Enbrel®.